Abstract
Dosage of serum AFP (alpha-fetoprotein) is widely used for HCC screening in patients with chronic liver disease. Virus-related chronic liver disease is the main cause of cirrhosis and HCC in Western and Far Eastern countries, but the relationship between viral etiology and AFP levels in HCC is still unclear. The aim of this study was to verify, in Western patients with post-viral chronic liver disease, the usefulness of AFP dosage for the detection of HCC, and the influence of viral etiology on AFP levels in HCC.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 1654-1658 |
| Numero di pagine | 5 |
| Rivista | Hepato-Gastroenterology |
| Volume | 47 |
| Stato di pubblicazione | Pubblicato - 2000 |
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
-
SDG 3 Salute e benessere
Keywords
- Biological Markers
- Carcinoma, Hepatocellular
- Chronic Disease
- Female
- Hepatitis B, Chronic
- Hepatitis C, Chronic
- Humans
- Italy
- Liver Diseases
- Liver Neoplasms
- Logistic Models
- Male
- Middle Aged
- Predictive Value of Tests
- Sensitivity and Specificity
- alpha-Fetoproteins
Fingerprint
Entra nei temi di ricerca di 'Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver